{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T13:47:56Z","timestamp":1788616076892,"version":"build-2803163510"},"reference-count":59,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>This study compared the survival of persons with secondary acute myeloid leukemia (sAML) to those with de novo AML (dnAML) by age at AML diagnosis, chemotherapy receipt, and cancer type preceding sAML diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from Surveillance, Epidemiology, and End Results 17 Registries were used, which included 47,704 individuals diagnosed with AML between 2001 and 2018. Multivariable Cox proportional hazards regression was used to compare AML\u2010specific survival between sAML and dnAML. Trends in 5\u2010year age\u2010standardized relative survival were examined via the Joinpoint survival model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, individuals with sAML had an 8% higher risk of dying from AML (hazard ratio [HR],\u00a01.08; 95% confidence interval [CI],\u00a01.05\u20131.11) compared to those with dnAML. Disparities widened with younger age at diagnosis, particularly in those who received chemotherapy for AML (HR,\u00a01.14; 95% CI,\u00a01.10\u20131.19). In persons aged 20\u201364\u00a0years and who received chemotherapy, HRs were greatest for those with antecedent myelodysplastic syndrome (HR,\u00a02.04; 95% CI,\u00a01.83\u20132.28), ovarian cancer (HR,\u00a01.91; 95% CI,\u00a01.19\u20133.08), head and neck cancer (HR,\u00a01.55; 95% CI,\u00a01.02\u20132.36), leukemia (HR,\u00a01.45; 95% CI,\u00a01.12\u20131.89), and non\u2010Hodgkin lymphoma (HR,\u00a01.42; 95% CI,\u00a01.20\u20131.69). Among those aged \u226565 years and who received chemotherapy, HRs were highest for those with antecedent cervical cancer (HR,\u00a02.42; 95% CI,\u00a01.15\u20135.10) and myelodysplastic syndrome (HR,\u00a01.28; 95% CI,\u00a01.19\u20131.38). The 5\u2010year relative survival improved 0.3% per year for sAML slower than 0.86% per year for dnAML. Consequently, the survival gap widened from 7.2% (95% CI,\u00a05.4%\u20139.0%) during the period 2001\u20132003 to 14.3% (95% CI,\u00a012.8%\u201315.8%) during the period 2012\u20132014.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Significant survival disparities exist between sAML and dnAML on the basis of age at diagnosis, chemotherapy receipt, and antecedent cancer, which highlights opportunities to improve outcomes among those diagnosed with sAML.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.35214","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T13:04:05Z","timestamp":1705755845000},"page":"1952-1963","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt"],"prefix":"10.1002","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3397-0591","authenticated-orcid":false,"given":"Ephrem","family":"Sedeta","sequence":"first","affiliation":[{"name":"Brookdale University Hospital Medical Center  Brooklyn New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0000-4111","authenticated-orcid":false,"given":"Ahmedin","family":"Jemal","sequence":"additional","affiliation":[{"name":"Surveillance and Health Equity Science American Cancer Society  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Nisotel","sequence":"additional","affiliation":[{"name":"Surveillance and Health Equity Science American Cancer Society  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8021-5997","authenticated-orcid":false,"given":"Hyuna","family":"Sung","sequence":"additional","affiliation":[{"name":"Surveillance and Health Equity Science American Cancer Society  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010020\u20100917\u20107"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010022\u201001613\u20101"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.60.0890"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23908"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_199519"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5625"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon\u20102016\u20100048"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2021.101929"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2006.10.006"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2020"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0465"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017008227"},{"key":"e_1_2_9_14_1","volume-title":"SEER*Stat Database: Incidence\u2014SEER Research Plus Data, 17 Registries, Nov 2021 Sub (2000\u20132019)\u2014Linked to County Attributes\u2014Time Dependent (1990\u20132019) Income\/Rurality, 1969\u20132020 Counties"},{"key":"e_1_2_9_15_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_9_16_1","volume-title":"SEER Cause of Death Recode"},{"key":"e_1_2_9_17_1","volume-title":"SEER Cause\u2010Specific Death Classification"},{"key":"e_1_2_9_18_1","volume-title":"Expected Survival Life Tables for SEER*Stat Software"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgu024"},{"key":"e_1_2_9_20_1","volume-title":"JPSurv: Joinpoint Survival Model"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467\u2010985x.2009.00580.x"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055\u20109965.epi\u201021\u20100423"},{"key":"e_1_2_9_23_1","volume-title":"Health Disparities Calculator (HD*Calc), Version 2.0.0","year":"2019"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.36255\/exon-publications-leukemia-secondary-acute-myeloid-leukemia"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403187"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102002\u201011\u20103343"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005335"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010022\u201001229\u2010z"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23220"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.05.009"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201008\u2010301713"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_239097"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24246"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426\u2010200007000\u201000008"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102006\u201001\u2010023101"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2013.09.013"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201003\u2010643544"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199902043400504"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.23.1932"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12052\u2010011\u20100373\u2010y"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046\u2010018\u20100859\u20103"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3155"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v89.9.3323"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20102141.2001.03043.x"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25598"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14509"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.6120"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1905447"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2008.04.012"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102008\u201007\u2010172007"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.03.186"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31543"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.73.7916"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2714"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00067"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010022\u201032103\u20108"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00428"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143583"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570163812666150602144310"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/mlr.0000000000000073"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.35214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:53:57Z","timestamp":1760266437000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.35214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,20]]},"references-count":59,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1002\/cncr.35214"],"URL":"https:\/\/doi.org\/10.1002\/cncr.35214","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,20]]},"assertion":[{"value":"2023-09-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}